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ABSTRACT
Background: Soluble ST2 (sST2) is released by strained myocardial. High baseline sST2 levels 
have been shown to be a predictor of mortality and heart failure in STEMI patients within 30 
days and within 1 year, but its effect on medium-term events has not been widely investigated.
Aims: To assess the prognostic factor of sST2 levels during admission with major cardiovascular 
events in the form of cardiovascular death and heart failure due to left ventricular dysfunction 
within 90 days of observation.
Methods: A retrospective cohort study was conducted on STEMI patients with an onset of ≤ 
24 hours undergoing reperfusion therapy from April 2014 - June 2015 in Dr. Sardjito General 
Hospital, Yogyakarta, Indonesia. The sST2 sample of venous blood was performed at admission. 
Primary outcomes for this analysis included cardiovascular death and congestive heart failure 
(CHF) through 90 days of follow-up. Assessment of major cardiovascular events was based 
on medical record data. Bivariate analysis were conducted on demographic and clinical factors 
related to sST2 and major cardiovascular events. A multivariate analysis was then conducted to 
determine the independent factors that influenced the emergence of major cardiovascular events.
Results: Of the 107 patients who met the subject criteria, there were 33 (30.8%) subjects with 
major cardiovascular events and 74 subjects (69.2%) without major cardiovascular events in 
90 days of observation. Of the 33 subjects with major cardiovascular events, there were 10 
subjects (9.3%) died and 23 subjects (21.5%) with heart failure. The sST2 levels did not have 
a significant relationship with the incidence of mortality (p=0.617), heart failure (p=1.000), or 
both combined (p = 1.000) in 90 days of observation.
Conclusion: High serum sST2 levels during admission in STEMI patients who had undergone 
reperfusion therapy were not associated with increased incidence of major cardiovascular events 
(either the incidence of mortality or heart failure alone or both combined) in 90 days observation.
Keywords: STEMI; soluble ST2; major cardiovascular events; mortality; heart failure
INTISARI
Latar Belakang: Biomarka sST2 dilepaskan oleh miokard yang mengalami regangan. Kadar 
sST2 fase awal yang tinggi telah terbukti sebagai predictor mortalitas dan gagal jantung pada 
pasien IMA-EST dalam 30 hari dan dalam 1 tahun, namun pengaruhnya terhadap kejadian 
jangka menengah belum banyak diteliti. Studi ini bertujuan untuk menilai faktor prognostic kadar 
sST2 saat admisi dengan kejadian kardiovaskular mayor (KKM) berupa kematian dan gagal 
jantung akibat disfungsi ventrikel kiri dalam 90 hari pengamatan.
Metode Penelitian: Penelitian kohort retrospektif dilakukan terhadap pasien IMA-EST dengan 
awitan ≤ 24 jam yang menjalani terapi reperfusi mulai April 2014-Juni 2015. Sampel sST2 dari 
darah vena dilakukan pada saat admisi. Pasien dinilai munculnya KKM dalam 90 hari pasca 
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IMA-EST berdasarkan data rekam medis. Analisis bivariate dilakukan terhadap faktor demografi 
dan klinis yang berhubungan dengan sST2 dan KKM. Analisis multi variate lalu dilakukan untuk 
mengetahui faktor independen yang mempengaruhi munculnya KKM.
Hasil: Dari 107 pasien yang memenuhi kriteria subjek penelitian, terdapat 33 (30,8%) subjek 
dengan KKM dan 74 subjek (69,2%) tanpa KKM selama 90 hari pengamatan. Dari 33 subjek 
dengan KKM, terdapat 10 subjek (9,3%) meninggal dan 23 subjek (21,5%) dengan gagal jantung. 
Kadar sST2 tidak memiliki hubungan yang signifikan dengan mortalitas (p=0,617), kejadian 
gagal jantung (p=1,000), maupun gabungan keduanya (p=1,000) dalam 90 hari.
Simpulan: Kadar sST2 serum yang tinggi saat admisi pada pasien IMA-EST yang telah 
menjalani terapi reperfusi tidak berhubungan dengan meningkatnya insidensi KKM (baik 
mortalitas atau kejadian gagal jantung saja maupun gabungan keduanya) selama 90 hari 
pengamatan pasca IMA-EST.
INTRODUCTION
In the United States, data from 2005-
2008, showed that in ST elevation myocardial 
infarction (STEMI) patient age ≥ 65 years, the 
median value of a 30-day mortality rate from 
acute myocardial infarction was 16.6% while 
readmission rate was 19.9%  for acute myocardial 
infarction and 24.4% for heart failure.1 Since the 
introduction of reperfusion therapy, percutaneous 
coronary intervention (PCI), antithrombotic 
therapy and secondary prevention treatment to 
date can reduce major adverse cardiovascular 
events (MACE) in hospitals by 50%. The hospital 
mortality rate also decreased from 7.2-12.5%.2 
The mortality rate in 1 year ranged from 7-18%.3 
Nevertheless, mortality rates and MACE still 
persisted at level of 12% which persisted up to 
6 months post-infarction observation in patients 
at high risk.4  Furthermore, the incidence of heart 
failure after myocardial infarction is about 20%.5 
Approximately 40% of myocardial infarction is 
followed by left ventricular systolic dysfunction.5 
The above facts indicate that the incidence 
of heart failure after myocardial infarction is a 
frequent occurrence.
Soluble ST2 (sST2) as one of the newly 
investigated biomarkers may be more specific 
in heart disease because it is released from 
stretched cardiomyocytes. Increased sST2 
levels in patients with myocardial infarction are 
associated with an increased risk of mortality 
and heart failure. 
In contrast to NT-proBNP, sST2 levels 
are not affected by age, previous heart failure 
status, atrial fibrillation, body mass index, or 
renal function obtained from studies involving 
the general and high risk population.6
Several large studies have concluded the 
role of high initial phase sST2 levels on MACE in 
STEMI patients within 30 days, 1and 3,5 years.7,8 
But few studies have examined the effect of sST2 
on mid-term MACE events in STEMI patients. 
Further studies need to be done to strengthen 
evidence of the role of sST2 in influencing the 
clinical course and the occurrence of heart failure 
in STEMI especially in the medium term. This 
study aims to investigate the role of high levels of 
sST2 measured at admission to the occurrence 
of MACE within 90 days in STEMI patients with 
reperfusion.
METHODS
This is a retrospective cohort study which 
is was part of previous study.9 In this current 
study, we continued to observe the occurrence 
of MACE of heart failure due to left ventricular 
dysfunction within 90 days after STEMI to see if 
baseline sST2 levels were associated with the 
occurrence of MACE (heart failure, readmission 
due to heart failure, cardiovascular mortality) in 
medium term.
The initial sampling of the research 
subjects was conducted in Emergency Room 
and Intensive Cardiac Care Unit (ICCU) Dr. 
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Sardjito General Hospital Yogyakarta, Indonesia 
from April 2014 until June 2015.9
The observations of the research subjects 
were carried out from the time of hospital 
treatment at ICCU Dr. Sardjito General Hospital, 
up to 90 days since the onset of STEMI attack 
where the data obtained from the results of 
medical record in Medical Record Installation of 
Dr. Sardjito General Hospital Yogyakarta or by 
phone if medical record data was not completely 
available.
The STEMI patients, age 30-75 years, 
with an onset ≤ 24 hours admitted via the 
Emergency Department of Dr. Sardjito General 
Hospital, Yogyakarta and undergoing reperfusion 
therapy with fibrinolysis or primary PCI on 
sitewere consecutively sampled andselected 
as research subjects. Exclusion criteria were a 
history of chronic renal failure stage IV, history 
of chronic heart failure before attack, hepatic 
cirrhosis, patients with pneumonia and/or 
chronic obstructive pulmonary disease acute 
exacerbations during hospitalization, patients 
with sepsis during hospitalization, patients with 
Killip class > II at admission, malignancy, patients 
who have undergone pre-admission fibrinolysis, 
patients with fibrinolysis failure, and incomplete 
medical records data where patients can not be 
contacted. 
Demographic data (gender, age, smoking 
status, history of diabetes mellitus, hypertension, 
and chronic accompanying diseases such as 
chronic kidney disease, chronic heart failure, 
hepatic cirrhosis, chronic obstructive pulmonary 
disease and malignancy), clinical profile (systolic 
and diastolic blood pressure, heart rate and 
Killip class), electro cardiogram, and laboratory 
features were collected and recorded in the 
case report form. An electro cardiogram (ECG) 
image is made with a 12-leads ECG. The right 
precordial leads (V2R, V3R and V4R) and 
posterior leads (V7, V8 and V9) are performed 
where necessary.
The ECG was assessed during admission 
and during hospitalization. Routine laboratory 
data include (1) hemoglobin, leukocyte count, 
platelet count, (2) creatinine (3) blood glucose 
at admission and (4) cardiac enzyme (creatine 
kinase (CK), CK-MB and troponin I).
Blood sampling and laboratory tests were 
performed during admission at the Emergency 
Room and 24 hours post-admission at ICCU 
Dr. Sardjito General Hospital and sent to the 
Clinical Pathology Laboratory Dr. Sardjito 
General Hospital for immediate routine checks. 
The admission blood sample was then treated 
for serum isolation.9
The sST2 is a glycoprotein and a family of 
the interleukin-1 receptor. sST2 is an isoform with 
a molecular weight of 60 kilo Dalton generated 
from alternate splicing of a transmembrane form 
with a molecular weight of 120 kDa.10 Samples 
for sST2 were taken from venous blood at the 
time of admission at the Dr. Sardjito General 
Hospital, stored in aliquot form on a micro 
tube and refrigerated at -80⁰C until analysis is 
performed. The sST2 levels were detected and 
measured by ELISA sandwich method with an 
R&D system kit.9
Reperfusion therapy includes fibrinolysis 
or primary PCI according to hospital procedures. 
Decisions on choice of reperfusion therapy 
were not influenced by this study. The subjects 
were then treated intensively at ICCU until 
stabilized for subsequent transfer to the ward 
or discharged.
During the 90 days since the onset of 
STEMI, based on medical record data, subjects 
were assessed against the occurence of MACE 
(heart failure, read mission due to heart failure, 
and cardiovascular death within 90 days of 
observation since the onset of STEMI. Death 
was mortality due to cardiovascular causes 
occurring within 90 days of observation since 
STEMI event by cardiovascular cause. Heart 
failureis defined as confirmed diagnosis of heart 
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failure, the administration of diuretic drugs, and 
the presence of signs and symptoms in medical 
record data. Heart failure readmission was 
defined as hospital care where heart failure was 
the main reason for hospitalization and requires 
management with diuretics, inotropes, or nitrates. 
The management of the subject at the time of 
treatment was performed solely by the physician 
in charge of the patient and was not influenced 
by this study. MACE were obtained from medical 
records and telephone confirmations of patients 
and families. Assessment was not influenced by 
the research and the assessor does not know 
the results of sST2 concentration on the subject.
Subjects were divided into two groups: 
groups with high serum sST2 (supramedian) and 
low serum sST2 group (inframedian). Baseline 
characteristics between the two groups was 
analyzed by chi-square test (for categorical 
data), Independent Sample T test (numerical 
data with normal distribution) and Mann-Whitney 
test (numerical data with abnormal distribution). 
The proportion of MACE within 90 days after 
STEMI between two groups was analysedby 
chi-square test. Multivariate analysis with 
confounding variables (p <0.25) that play a role 
in the occurance of MACE was done with logistic 
regression analysis,if necessary. The p value 
<0.05 was defined as the statistical significance 
limit. The analysis was performed with SPSS 
version 20.
This research has obtained ethical 
clearance approval from the Ethics Commission 
of Faculty of Medicine UGM and Dr. Sardjito 
General Hospital with reference number: No Ref: 
KE/FK/494/EC/2016.
RESULT
A total of 107 subjects were analyzed 
in this study. The median level of sST2 in this 
study subjects was 751.16 pg/mL. Minimum level 
obtained is 257.99 pg/mL, while the maximum 
level is 1029 pg/mL. The 25 and 75th percentile 
values  are 696.38 pg/mL and 824.81 pg/mL 
respectively. The result of data normality test by 
Klomogorov-Smirnov test showed that the sST2 
content was not normally distributed (p <0.05). 
This research uses cut off value of sST2 based 
on median (751.16 pg/mL).
The subjects were divided into two groups 
based on these values, ie group with sST2 ≤ 
751.16 pg/mL and group with sST2> 751.16 
pg/mL. Statistically, there were no significant 
differences in characteristics between the two 
groups. The basic characteristics of research 
subjects in STEMI patients are shown in Table 1.
There  were  33  (30 .8%)  sub jec ts 
experiencing MACE and 74 subjects (69.2%) 
who did not experience MACE for 90 days of 
observation. Of 33 subjects with MACE, there 
were 10 subjects (9.3%) died and 23 subjects 
(21.5%) with heart failure. Significantly different 
variables in both groups were based on combined 
MACE (mortality and incidence of heart failure), 
among others: age (p = 0.012), blood glucose 
level (p = 0.018), creatine kinase (p = 0.010), 
creatine kinase-MB (p = 0.004), and troponin 
I (p <0.001). The other variables did not differ 
significantly between the two groups (Table 2).
We compared the basic characteristics 
between the group experiencing death and those 
who did not. Significantly different variables in 
both groups based on mortality in this study were 
age variables (p = 0.032) and onset of infarction 
(p = 0.018). The other variables did not differ 
significantly between the two groups (Table 3).
When compared to the basic characteristics 
between groups experiencing heart failure and 
those who do not, there were significantly 
different variables in both groups in this study 
of active smokers (p = 0.047), anterior STEMI 
location (p = 0.042), blood glucose level (p = 
0.038), creatine kinase (p = 0.001), creatine 
kinase-MB (p = 0.002), and troponin I (p <0.001). 
The other variables did not differ significantly 
between the two groups (Table 4).
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Table 1.Comparison of baseline characteristics of group with high sST2 (> 751.16 pg/mL) and low (≤ 
751.16pg/mL) levels in STEMI with reperfusion
Characteristic
High sST2 Low sST2
p value
(n = 54) (n = 53)
Sex, n (%) 0.429
Male 46 (85.2) 41 (77.4)
Female 8 (14.8) 12 (22.6)
Age (year) 57.2 ± 9.4 56.9 ± 8.5 0.898
Diabetes mellitus, n (%) 11 (20.4) 15 (28.3) 0.465
Hypertension, n (%) 33 (61.1) 32 (60.4) 1.000
Active smoker, n (%) 32 (59.3) 30 (56.6) 0.934
Onset (hour)** 5 (2-24) 5 (2-24) 0.975
Systolic blood pressure (mmHg)** 137.5 (80-190) 130 (80-200) 0.225
Diastolic blood pressure (mmHg)** 80.5 (44-110) 80.0 (50-140) 0.475
Anterior STEMI, n (%) 28 (51.9) 24 (45.3) 0.627
Haemoglobin (g/dL)* 14.05 ± 1.9 14.07 ± 1.9 0.954
White Blood Cell (103/μL)* 13.4 ± 4.1 14.05 ± 3.92 0.382
Platelet (103/μL)** 242 (144-704) 268 (117-655) 0.106
Creatinine (mg/dL) * 1.16 ± 0.29 1.18 ± 0.30 0.864
Blood Glucose (g/dL)** 146.5 (89-566) 150 (86-521) 0.871
GOT (IU/L)** 44.5 (13-263) 44.0 (12-497) 0.911
Creatine kinase (IU/mL)** 681.5 (40-7404) 1053 (39-5884) 0.815
Creatine kinase – MB (IU/mL)** 77.5 (20-975) 95 (14-652) 0.786
Troponin I (ng/mL) ** 1.35 (0.01-44) 2.04 (0.01-30) 0.452
Reperfusion method, n (%) 0.203
 Primary PCI 28 (51.9) 20 (37.7)
Fibrinolysis 26 (48.1) 33 (62.3)
Heparin, n (%) 50 (92.6) 53 (100.0) 0.061
ACEi/ARB, n (%) 49 (90.7) 49 (92.5) 0.512
Beta blocker, n (%) 49 (90.7) 46 (86.8) 0.733
CCB, n (%) 11 (20.4) 7 (13.2) 0.464
Combined MACE, n (%) 16 (29.6) 17 (32.1) 0.949
Death, n (%) 5 (9.3) 5 (9.4) 0.617
Heart Failure, n (%) 11 (20.4) 12 (22.6) 0.960
MACE: major advance cardiovascular event, STEMI: ST-elevation myocardial infarction, GOT: glutamic 
oxaloacetate transaminase, PCI: percutaneous coronary intervention, ACEi: angiotensin converting enzyme 
inhibitor, ARB: angiotensin receptor blocker. CCB: calcium channel blocker.
*normal data distribution, presented as mean and standart deviation, analysed with unpaired T-test
**abnormal data distribution, presented as median (minimum-maximum), analysed with Mann-Whitney test.
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Table 2. Comparison of baseline characteristics based on a combined MACE event for 90 days in 
STEMI patients with reperfusion
Characteristic
MACE (+) MACE (-)
P value
(n = 33) (n = 74)
Sex, n (%) 0.152
Male 30 (90.9) 57 (77)
Female 3 (9.1) 17 (23)
Age (year)* 60.3 ± 9.3 55.6 ± 8.4 0.012
Diabetes mellitus, n (%) 10 (30.3) 16 (21.6) 0.470
Hypertension, n (%) 23 (69.7) 42 (56.8) 0.293
Active smoker, n (%) 24 (72.7) 38 (51.4) 0.063
Onset (hour)** 6 (2-24) 5 (2-24) 0.321
Systolic blood pressure (mmHg)** 125 (80-190) 130 (80-200) 0.787
Diastolic blood pressure (mmHg)** 80 (50-110) 80 (44-140) 0.651
Anterior STEMI, n (%) 21 (63.6) 31 (41.9) 0.062
Haemoglobin (g/dL)* 13.8 ± 2.1 14.2 ± 1.9 0.377
White Blood Cell (103/μL)* 14.4 ± 4.2 13.4 ± 3.9 0.238
Platelet (103/μL)** 238 (144-655) 266.5 (117-704) 0.166
Creatinine (mg/dL)* 1.20 ± 0.27 1.16 ± 0.31 0.527
Blood Glucose (g/dL)** 168 (102-521) 141 (86-566) 0.018
GOT (IU/L)** 48 (12-263) 44 (14-497) 0.522
Creatine kinase (IU/mL)** 1564 (39-5884) 464 (40-7404) 0.010
Creatin kinase–MB (IU/mL)**
Troponin I (ng/mL)**
160 (25-975)
7.30 (0.03-44)
68.5 (14-652)
0.49 (0.01-30)
0.004
< 0.001
Reperfusion method, n (%) 0.120
 Primary PCI 19 (57.6) 29 (39.2)
Fibrinolysis 14 (42.4) 45 (60.8)
Heparin, n (%) 32 (97.0) 71 (95.9) 0.637
ACEi/ARB, n (%) 32 (97.0) 66 (89.2) 0.170
Beta blocker, n (%) 28 (84.8) 67 (90.5) 0.290
CCB, n (%) 3 (9.1) 15 (20.3) 0.251
sST2 (pg/mL)* 737.03 ± 130.67 755.09 ± 117.33 0.479
MACE: major advance cardiovascular event, STEMI: ST-elevation myocardial infarction, GOT: glutamic 
oxaloacetate transaminase, PCI: percutaneous coronary intervention, ACEi: angiotensin converting enzyme 
inhibitor, ARB: angiotensin receptor blocker. CCB: calcium channel blocker.
*normal data distribution, presented as mean and standart deviation, analysed with unpaired T-test
**abnormal data distribution, presented as median (minimum-maximum), analysed with Mann-Whitney test.
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Table 3. Comparison of baseline characteristics based on mortality within 90 days in STEMI patients 
with reperfusion
Characteristic
Mortality (+) Mortality (-)
p value
(n = 10) (n = 97)
Sex, n (%) 0.406
Male 9 (90) 78 (80.4)
Female 1 (10) 19 (19.6)
Age (year)* 62.8 ± 9.2 56.5 ± 8.7 0.032
Diabetes mellitus, n (%) 2 (20) 24 (24.7) 0.544
Hypertension, n (%) 6 (60) 59 (60.8) 0.606
Active smoker, n (%) 6 (60) 56 (57.7) 0.584
Onset (hour)* 11.8 ± 9.2 7.1 ± 5.5 0.018
Systolic blood pressure (mmHg)* 123.3 ± 24.5 132.7 ± 24.8 0.337
Diastolic blood pressure (mmHg)**
Anterior STEMI, n (%)
80 (50-90)
5 (50)
80 (44-140)
47 (48.5)
0.824
0.593
Haemoglobin (g/dL)* 13.2 ± 2.2 14.1 ± 1.9 0.145
White blood cell (103/μL)* 15.7 ± 4.8 13.5 ± 3.9 0.106
Platelet (103/μL)* 264.1 ± 149.1 270.3 ± 86.9 0.843
Creatinine (mg/dL)* 1.3 ± 0.25 1.2 ± 0.30 0.138
Blood Glukose (g/dL)* 235.9 ± 150.3 189.8 ± 100.4 0.192
GOT (IU/L)** 85.3 ± 88.7 81.88 ± 86.2 0.906
Creatine kinase (IU/mL)* 566 (39-5113) 861 (40-7404) 0.753
Creatine kinase–MB (IU/mL)** 69 (26-509) 90 (14-975) 0.872
Troponin I (ng/mL)** 2.92 (0.03-30) 1.89 (0.01-44) 0.322
Reperfusion method, n (%) 0.089
 Primary PCI 7 (70) 41 (42.3)
Fibrinolysis 3 (30) 56 (57.7)
Heparin, n (%) 10 (100) 93 (95.9) 0.671
ACEi/ARB, n (%) 9 (90) 89 (91.8) 0.601
Beta blocker, n (%) 7 (70) 88 (90.7) 0.083
CCB, n (%) 1 (10) 17 (17.5) 0.470
sST2 (pg/mL)* 726.1 ± 167.1 751.9 ±  116.4 0.523
STEMI: ST-elevation myocardial infarction, GOT: glutamic oxaloacetate transaminase, PCI: percutaneous coronary 
intervention, ACEi: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker. CCB: calcium 
channel blocker.
*normal data distribution, presented as mean and standart deviation, analysed with unpaired T-test
**abnormal data distribution, presented as median (minimum-maximum), analysed with Mann-Whitney test.
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Table 4. Comparison of baseline characteristics based on the incidence of heart failure in 90 days in 
STEMI patients with reperfusion
Characteristic
Heart Failure (+) Heart Failure (-)
p value
(n =23) (n =84)
Sex, n (%) 0.137
Male 21 (91.3) 66 (78.6)
Female 2 (8.7) 18 (21.4)
Age (year)* 59.2 ± 9.4 56.5 ± 8.7 0.204
Diabetes mellitus, n (%) 8 (34.8) 18 (21.4) 0.294
Hypertension, n (%) 17 (73.9) 48 (57.1) 0.223
Active smoker, n (%) 18 (78.3) 44 (52.4) 0.047
Onset (hour)** 5 (2-24) 5 (2-24) 0.725
Systolic blood pressure (mmHg)* 134  ± 24.2 131 ± 25.1 0.635
Diastolic blood pressure (mmHg)** 82 (60-110) 80 (44-140) 0.505
Anterior STEMI, n (%) 16 (69.6) 36 (42.9) 0.042
Haemoglobin (g/dL)* 14.1 ± 2.0 14.1 ± 1.9 0.972
White blood cell (103/μL)* 13.8 ± 3.8 13.7 ± 4.0 0.854
Platelet (103/μL)* 254 ± 65.7 274 ± 99.6 0.365
Creatinine (mg/dL)* 1.15 ± 0.27 1.18 ± 0.31 0.737
Blood Glukose (g/dL)** 167 (102-367) 142 (86-566) 0.038
GOT (IU/L)** 48 (13-263) 44 (12-497) 0.341
Creatine kinase (IU/mL)** 1631 (180-5884) 480 (39-7404) 0.001
Creatine kinase–MB (IU/mL)** 163 (25-975) 68 (14-652) 0.002
Troponin I (ng/mL)* 14.07 ± 12.58 4.89 ± 8.70 < 0.001
Reperfusion method, n (%) 0.576
 Primary PCI 12 (52.2) 36 (42.9)
Fibrinolysis 11 (47.8) 48 (57.1)
Heparin, n (%) 22 (95.7) 81 (96.4) 0.626
ACEi/ARB, n (%) 23 (100) 75 (89.3) 0.103
Beta blocker, n (%) 21 (91.3) 74 (88.1) 0.500
CCB, n (%) 2 (8.7) 16 (19.0) 0.198
sST2 (pg/mL)* 741.79 ± 115.49 751.64 ± 123.38 0.732
STEMI: ST-elevation myocardial infarction, GOT: glutamic oxaloacetate transaminase, PCI: percutaneous 
coronary intervention, ACEi: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker. CCB: 
calcium channel blocker.
*normal data distribution, presented as mean and standart deviation, analysed with unpaired T-test 
**abnormal data distribution, presented as median (minimum-maximum), analysed with Mann-Whitney test.
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The univariate analysis of sST2 with 
cut-off value of 751.16 pg/mL was performed 
on combined MACE in STEMI patients with 
reperfusion therapy. The proportion of subjects 
experiencing MACE was slightly lower in the 
supramedian group (48.5%) than infra median 
groups ST2 (50%). However, the difference 
value was not statistically significant (OR, 0.94; 
95% CI, 0.41 to 2.14; P=1.000). Similarly, when 
univariate analysis of sST2 levels was performed 
on mortality and the incidence of heart failure 
in 90 days, the sST2 levels did not have a 
significant relationship (OR, 1.02; 95% CI, 0.28 
to 3.75; P=0.167 and OR, 0.92; 95% CI, 0.36 to 
2.31; P=1.000, respectively).
DISCUSSION
Suppression of Tumorigenicity 2 (ST2) is 
a member of the family of interleukin receptor 
proteins (IL) -1 with two main isoforms in 
transmembrane or cellular form (ST2L) and 
soluble (sST2) that can circulate in serum. ST2 
was first described in 1989. The human ST2 
gene lies on the 2q12 chromosome and is part 
of a larger group of IL-1 genes. Transcription of 
this gene produces four isoforms (sST2, ST2 
ligand (ST2L), ST2V and ST2LV), of which two 
of the above have the most important role. The 
ST2 gene exhibits two promoters: the proximal 
and distal portions, which are capable of affecting 
the mechanism of gene transcription regulation. 
Each promoter has an effect on the expression 
of sST2 and ST2L mRNA. Genetic factors alone 
affect up to 40% of the variability of sST2 levels 
between individuals.11
The majority of heart failure cases 
post-myocardial infarction was due to loss of 
normal myocardium resulting from myocardial 
infarction resulting in mechanical overload of 
the still viable myocardium. This mechanical 
overload causes myocardial growth as a 
compensatory mechanism so that a hypertrophic 
myocardium can produce greater pressure. 
Several pathophysiological pathways, such 
as angiotensin II, endothelin-1 and natriuretic 
factors play a role in this mechanical overload 
process. The contractile element of myocyte and 
disc of Z is a mechanotransducer which conducts 
mechanical forces in the myocardium.12
Cardiomyocyte hypertrophy and cardiac 
fibrosis are common in acute MI patients. ST2 
mRNA is strongly initiated in the myocytic heart 
cells when subjected to mechanical strain or 
with IL-1β administration, and serum sST2 levels 
are increased while in rat experimental animals 
performed ligases in their coronary arteries.13
IL-33 is a biomechanically precipitated 
protein in cardiac fibroblast cells in which the 
effect is in contrast to cardiomyocyte hypertrophy 
induced by angiotensin II and phenylephrine.14
This study attempted to find out the 
relationship between measurement of sST2 levels 
at admission to MACE incidence in 90 days in the 
form of death due to cardiovascular causes, heart 
failure, and heart failure readmission in STEMI 
patients who had undergone reperfusion therapy. 
In this study, the sST2 levels at admission did 
not have prognostic factors, either on combined 
MACE events, nor with mortality and the 
incidence of heart failure alone, within 90 days 
of STEMI onset. 
This result differs from that of O’Donoghue 
et al. which stated that STEMI patients with high 
levels of sST2, troponin T and mieloperoksidase 
(MPO) have a higher risk of cardiovascular and 
cardiovascular death within 30 days compared 
with those who do not.15
These three biomarkers have different 
pathobiological axes: myocardial strains, 
myocyte necrosis, and inflammation. In the 
study, sST2 has a weak correlations with other 
strain biomarkers such as BNP, galectin-3, and 
troponin T. Similar phenomena are also found 
in NSTEMI. Experts hypothesize that ST2 does 
not merely play a role in myocardial strain, but 
also in the inflammatory, fibrosis, and myocardial 
10  
Hutomo et al., 2017
remodeling processes. However, unlike this 
study in which primary PCI and fibrinolysis were 
included as reperfusion modalities, the subjects 
in the study were STEMI patients undergoing 
fibrinolysis.
In this study, the median value of sST2 
is 751.16 pg/mL. Minimum level obtained is 
257.99 pg/mL, while the maximum level is 1029 
pg/mL. The 25 and 75th percentile values  are 
696.38 pg/mL and 824.81 pg/mL respectively. 
The detection method used in this study was the 
ELISA sandwich technique that was sensitive in 
detecting the levels of a protein in the serum. The 
sST2 levels obtained in the study by Shimpo et 
al. in STEMI patients is between 85 – 6880 pg/
mL with a median value of 235 pg/mL.16 Serum 
sST2 levels obtained in the study by Hartopo et 
al. ranged from 257.99 pg/mL to 1006.21 pg/mL 
with median 751.16 pg / mL.9
In both studies, blood samples were taken 
at the beginning of the patient’s arrival with 
STEMI. The level of sST2 in this study was higher 
than that of sST2 in the study of Sabatine et al. in 
STEMI patients where the median value of 80 pg/
mL with the 25th and 75th percentile values  was 
0 and 325 pg/mL respectively.17 In the study by 
Weir et al.,median of sST2 was 263.30pg/mL with 
interquartile range of 139.40pg/mL to 491.50pg/
mL.18 In the study byDemyanets et al. showed 
median serum sST2 level of 453 pg/mL with 
interquartile range of 313pg/mL to 688pg/mL.7
Nevertheless, in all three studies, indirect 
blood samples were taken at the patient’s initial 
presentation. Weir et al. took serum samples 
within 1-2 weeks after acute myocardial infarction 
while Sabatine et al. and Demyanets et al. took a 
serum sample just before the patient underwent 
coronary angiography (2-8 days after onset of 
attack).7,17,18
There is a variation in the sST2 levels 
obtained in this study compared with some 
previous studies which may be due to differences 
in the assay kits used and the sampling times 
are not the same in each study. Nevertheless, 
the results of this study are consistent with 
those studies where there is an increase in 
sST2 levels at the onset of STEMI. Ex-vivo 
data from myocardial myocyte cells undergoing 
biomechanical strain showed that the maximum 
induction of ST2 transcription occurred at 2 
hour, lasted for 9 hour and began to decrease 
at the 15th hour.17 Increased levels of sST2 
during admission prove that at the beginning of 
myocardium, acute phase remodeling process 
has begun to occur.
Mean serum sST2 levels in healthy normal 
individuals were 10 ng/mL (range 5-34 ng/
mL) but the results were assessed by ELISA 
technique using Presage ST2 assay kit. The 
results can not be interpolated with the ELISA 
R&D system used in this study because there 
has never been a healthy sST2 level examination 
in healthy individuals with this kit before.19
Study by Hughes et al. in healthy individuals 
with cardiovascular risk factors showed that 
sST2 levels were higher in men (mean 30.4 ng/
mL) than women (mean 23.8 ng/mL).6
Similarly, study by Dieplinget et al. in 
healthy Austrian population, sST2 mean levels 
of 4-31 ng/mL were obtained in men and 2-21 
ng/mL for women.20 In this study, median values 
of sST2 were higher in men (764.79 pg/mL) than 
in women (733.74 pg/mL).
Characteristic description between groups 
with high sST2 (>751.16 pg/mL) and low sST2 
(≤751.16 pg/mL) group included demographic 
characteristics and clinical characteristics. 
Statistically, there were no significant differences 
between the two groups.
These results are similar to those study 
of Sabatine et al. whereas sST2 levels at the 
beginning of presentation, in contrast to NT-
proBNP levels, are not associated with clinical 
characteristics that potentially affect chronic 
elevation of left ventricular wall pressure such 
as age, sex and hypertension, previous history 
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of myocardial infarction and previous history of 
congestive heart failure.17
In the study, the sST2 levels were strongly 
correlated with creatine kinase levels. Study by 
Demyanets et al. showed that sST2 levels were 
positively correlated with creatinine levels, but 
not with classic cardiovascular risk factors such 
as age, diabetes, hypertension, dyslipidemia, 
obesity, and smoking.7 Serum sST 2 levels are 
not affected by fasting conditions, body mass 
index, and renal function.20
In the study by Shimpo et al.,sST2 levels 
have a weak association with troponin I levels 
and are not associated with plasma BNP levels, 
as did study by Weir et al.16,18This reflects that 
ST2 patophysiology is different from other 
commonly used biomarkers.
In this study, there were no significant 
differences from systolic and diastolic blood 
pressure on admission of the two sST2 groups. 
During observation, the hemodynamic factor 
at admission does not affect the occurrence of 
MACE.
This result differs from the study by Shimpo 
et al. which showed that the sST2 level on 
admission was associated with higher heart rate 
and greater systolic blood pressure despite no 
clinically significant hemodynamic disturbance 
in the study.16
All subjects in this study underwent 
primary PCI revascularization consisted of 48 
subjects and fibrinolysis in 59 subjects. There 
is no difference between the two modalities 
of revascularization among subjects with high 
levels of ST2 and subjects with low levels of ST2. 
In some previous studies, levels of ST2 can be a 
predictor of MACE events in the form of mortality 
and the incidence of heart failure both short- and 
long-term.7,8,16,17
Modality of reperfusion therapy in the study 
were fibrinolysis, in contrast to the population 
in this study where primary PCI was included 
as one of the modality of reperfusion therapy. 
Reperfusion therapy with primary PCI is superior 
because it can restore coronary flow, reduce 
infarct size, increase fraction ejection and 
improve outcomes better than fibrinolysis.4,8 
Authors hypothesized that patients who received 
primary PCI were having fewer cell damage 
progression which affected the incidence of 
MACE later in life. In this study, primary PCI 
was not a factor that independently affected the 
incidence of mortality and heart failure within 
90 days.
The study by Weir et al. showed that serum 
sST2 levels did not differ significantly between 
anterior/anterolateral, inferior/inferiorosterior and 
lateral location.18
 In this study, there was no significant 
difference in the type of infarct location in the two 
groups of sST2 levels but anteriorSTEMIlocation 
increased the risk of MACE by 2.43 times (p = 
0.012). When associated with the incidence of heart 
failure within 90 days, anterior STEMI increased 
the risk of heart failure by 3.05 (p = 0.020). In the 
anterior STEMI, the strain experienced by the left 
ventricle is greater than that of the other STEMI 
sites. Study conducted by Shimpo et al. showed 
significantly higher anterior STEMI proportions in 
subjects with sST2 levels above the third quartile.16  
In this study, there was no significant difference in 
proportion between groups with high sST2 levels 
and with low sST2 levels.
Treatment of patient in this study was 
administered in accordance with hospital 
guideline standards. Aspirin, clopidogrel, and 
heparin are given as indicated. Other drugs such 
as ACEi or ARB and beta blockers are given if 
there is no contraindication. Statin therapy is 
routinely administered to all patients. There was 
no significant difference in drug management in 
the high sST2 group and low sST2. At 90-day 
observations, the drugs were not associated with 
the risk of MACE, mortality and heart failure. In 
a study by Weir et al. in patients with high sST2 
levels, the administration of eplerenone therapy 
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(an aldosterone antagonist) is said to have been 
shown to decrease the progression of ventricular 
remodeling after STEMI.18
In this study, no subjects received 
eplerenone therapy or other aldosterone 
antagonistic drugs during the observation period.
LIMITATIONS
This study use retrospective design so 
recall bias may happens and data on medical 
record depends on the consideration of the 
clinician handling the case at that time. The total 
number of subjects in this study does not meet 
the minimal number of samples required and also 
the proportion of subjects in the group with MACE 
in this study (33 subjects) was also inadequate 
for the minimal proportion required (136 subjects) 
to achieve a research strength of 20%.
This study conclude that in STEMI patients 
who had undergone reperfusion with high serum 
sST2 levels at admission, the risk of MACE for 
90-days after STEMI (either mortality or the 
incidence of heart failure alone or both combined) 
was not higher than in low serum sST2 level.
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